Roche acquires GenMark Diagnostics for $1.8 billion

Roche has acquired GenMark Diagnostics for $1.8 billion, the group announced in a statement. GenMark provides molecular diagnostic tests that are designed to detect multiple pathogens from a single patient sample. The merger agreement has been unanimously approved by the boards of directors of GenMark Diagnostics and Roche. 

Once the acquisition is completed, GenMark’s core operations will continue to be conducted from its offices in Carlsbad, California, USA. Under the terms of the agreement, Roche will launch a tender offer to acquire all outstanding shares of GenMark. GenMark’s portfolio of syndromic panel tests will complement the Swiss pharma’s existing molecular diagnostics portfolio.   

If you want to read more about the Swiss biotech company Roche and to find more details about the acquisition of the GenMark Diagnostics group, download for free the Born2Invest mobile app. Available for both Android and iOS devices, our companion app brings you the latest and most important financial news of the day.

Roche achieved a net profit of $15.76 billion (€13.21 billion) in 2020, up 6% from 2019 

“The acquisition of GenMark Diagnostics will expand our molecular diagnostics portfolio to include solutions that can provide life-saving information quickly to patients and their healthcare providers in the fight against infectious diseases,” as explained by Thomas Schinecker, CEO of Roche. 

The Swiss drugmaker, which counts Citi as a financial advisor, and Sidley Austin as a legal advisor, is confident of closing the transaction in the second quarter of 2021. JP Morgan Securities is acting as financial advisor to GenMark and DLA Piper as legal advisor. Roche posted a net income of $15.76 billion (€13.21 billion) in 2020, up 6% from 2019. The group posted revenues of $66.78 billion (€55.97 billion) in the last financial year, 5% less than in 2019. By business segment, the pharmaceuticals division contracted by 8.2% to $49.12 billion (€41.17 billion). The diagnostics division, meanwhile, posted revenue of $15.2 billion (€12.75 billion), up 6.5%. 

Roche reduced cost of sales by 12% to 14,957 million euros, while marketing and distribution expenses were $10.56 billion (€8.85 billion), down 13%. General and administrative costs contracted by 26% to $3.63 billion (€3.04 billion).

Roche recorded an ebitda of $26.8 billion (€22.45 billion) in 2020, 4.5% less than in 2019  

Research and development increased by 2%, to (€12.03 billion). Roche ended 2020 with a gross operating result (Ebitda) of $26.8 billion (€22.45 billion), 4.5% less than in 2019. “We developed a broad portfolio of diagnostic solutions in record time and entered into new alliances to develop and produce effective medicines against Covid-19,” explained the group’s CEO, Severin Schwan.

__

(Featured image by felixioncool via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.